Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2020-09-08 Regulatory Filings
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in relation to our intimation of outcome ....
Regulatory Filings
2020-09-08 English
Pursuant to 129, 134 and other applicable provisions of the Companies Act, 2013 including rules made thereunder, the Board has approved and recommended the Annual audited financial statements ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) reporting the outcome of a Board Meeting held on August 28, 2020. It informs about the approval of the Annual Audited Financial Statements for the fiscal year ended March 31, 2020, the scheduling of the Annual General Meeting (AGM) for October 17, 2020, and the declaration of the final dividend. The document does not contain the full Annual Report or the financial statements themselves but announces the approval and plans related to them. The document length is 2534 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of board meeting outcomes and related regulatory disclosures, not the full Annual Report or financial statements.
2020-08-28 English
Pursuant to the applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation ....
Regulatory Filings
2020-08-27 English
Fermenta Biotech Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on August 28, 2020, inter alia, to consider adoption of annual audited ....
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider adoption of annual audited financial statements, convening of the annual general meeting, and recommendation of final equity dividend. It also includes information about the closure of the trading window as per SEBI regulations. The document is a formal announcement to the stock exchange (BSE Limited) about the upcoming board meeting and trading restrictions, not the actual annual report or financial statements. The document length is short (2643 characters) and it does not contain any financial data or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a regulatory announcement related to corporate governance and compliance but not a full report or presentation.
2020-08-25 English
Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/08/2020 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider adoption of annual audited financial statements, convening of the annual general meeting, and recommendation of final equity dividend. It also includes information about the closure of the trading window as per SEBI regulations. The document is a formal announcement informing the stock exchange and public about the upcoming board meeting and trading restrictions, but it does not contain any financial statements or detailed report content itself. The document length is 2643 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) since it is a regulatory announcement that does not fit into other specific categories like Annual Report or Board/Management Information (which would require actual changes or detailed disclosures).
2020-08-25 English
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith photocopy of the newspaper ....
Regulatory Filings
2020-08-20 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.